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Purpose: Intensity modulated proton therapy (IMPT) allows for 
the delivery of ionizing radiation over a well-defined range with 
minimal exit dose compared to photons, and may further 
improve dose conformality compared to other proton modalities. 
IMPT is not available for brain cancer treatment in Canada. 
Instead, patients who would likely benefit from proton over 
photon therapy are evaluated on a case-by-case basis for referral 
to US facilities. Improved neurocognitive outcomes would 
certainly constitute a strong argument. As such, tools were 
developed to estimate the intelligence quotient (IQ) and the risk 
of hearing loss post radiotherapy and to compare outcomes of 
proton against photon in pediatric brain tumours on a case-by-
case basis. 
Methods and Materials: Pediatric patients who had received 
radical photon intensity modulated radiation therapy (IMRT) 
were randomly selected from our retrospective database: 10 
cases each of craniopharyngioma, ependymoma and 
medulloblastoma, and 20 cases of glioma. The existing planning 
CT and contoured structures were used to generate IMPT plans 
employing a robust optimization procedure. The RBE-corrected 
dose to brain structures and the cochleas were calculated for 
both IMPT and IMRT. A dose dependent IQ model was applied to 
estimate IQ using a Markov chain Monte Carlo technique. 
Cumulative probability distributions (CDF) were calculated to 
perform a statistical interpretation and to compare proton versus 
photon outcomes. The reported incidence of hearing loss as a 
function of cochlear dose in the literature was used to estimate 
the probability of occurrence. 
Results: The average dose to the brain was less in all IMPT plans 
compared to IMRT: ranging from a 6.7% reduction (p = 0.003) in 
the case of medulloblastoma to 38% (p = 0.007) for 
craniopharyngioma. This dose reduction translated into a gain in 
IQ of 1.9 points on average for protons versus photons for the 
whole cohort at five years post-treatment (p = 0.011). In terms 
of specific diseases, the gains in IQ points were 0.8, 1.6, 2.3, and 
2.7 for medulloblastoma, ependymoma, glioma and 
craniopharyngioma, respectively. When estimating the IQ using 
dose to the temporal lobes, these gains increased to 3.1 to 6.0 
IQ points. Overall, the probability for IQ deficits ≥ 7.5 points was 
estimated to be 32% for IMPT compared to 48% for IMRT, an 
absolute reduction of 16% for the whole cohort (p = 0.014). 
Hearing loss probability was evaluated on a per-ear-basis and was 
found to be systematically less for proton versus photon: 2.9% 
versus 7.2% (p < 10-7). 
Conclusions: IQ predictions post IMPT and IMRT were found to 
be very similar, but a modest gain was systematically observed 
for proton in all patients. Given the uncertainties within the IQ 
model used and our reinterpretation, the predicted gains may be 
underestimated. Additional long-term clinical studies are needed 
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Purpose: Patient outcomes with dose escalation for high-grade 
gliomas have been disappointing because of non-central relapses 
and radionecrosis. Dose-painting can maximize central disease 
control, while minimizing the risk of radionecrosis. This study 
aimed to determine whether dose painting with volumetric 
modulated arc therapy (VMAT) for high-grade gliomas using 3,4-
dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-FDOPA) positron 
emission tomography (PET) could achieve dose-escalated 
coverage of biological target volumes (BTVs) without increasing 
the dose to cranial organs at risk (OARs). 
Methods and Materials: Computed tomography, magnetic 
resonance imaging (MRI) and 18F-FDOPA PET/CT images were 
obtained for post-operative radiation therapy planning of 10 
patients with high-grade glioma. The gross tumour volume (GTV) 
was contoured by a radiation oncologist using gadolinium-
enhanced T1 and T2 FLAIR MRI. The clinical target volume (CTV) 
was defined as a 2 cm expansion of the GTV and surgical cavity. 
The planning target volume (PTV) was defined as a 0.5 cm 
expansion of the CTV. Two VMAT plans (Eclipse version 11.031, 
Varian Medical Systems, Palo Alto, CA) were generated for each 
patient: a conventional VMAT plan without dose escalation with 
a prescribed dose of 60 Gy in 30 fractions in the PTV and a plan 
with dose escalation up to a maximum dose of 80 Gy. The BTVs 
were created by thresholding the 18F-FDOPA uptake on PET/CT 
using a linear quadratic model that assumed tracer uptake was 
linearly related to tumour cell density in each image voxel and 
required the number of surviving tumour cells in each voxel to 
be the same. The treatment planning OARs were: brainstem, 
optics (combined optic nerves and chiasm), anterior chambers, 
and retinas. Dose conformity was quantified using van’t Reit’s 
conformation number. Mean OAR and maximum doses were 
compared using two-sided paired t tests (α = 0.05). 
Results: The mean volume of the PTV receiving 95% of the 
prescribed dose (V95%) was 99.1% with and 99.1% without dose-
painting (p = 0.6). The average PTV conformation number was 
high for plans with (0.92) and without (0.93) dose painting. The 
mean V95% was 98.7% for BTV65, 94.6% for BTV70 and 97.2% for 
BTV75. The patient-averaged mean doses were 64.3 Gy for 
BTV65, 68.5 Gy for BTV70, and 73.9 Gy for BTV75. The patient-
averaged maximum doses to the brainstem (43.6 Gy versus 44.5; 
p = 0.9), optics (25.8 Gy versus 25.9 Gy; p = 0.8), anterior 
chambers (5.8 Gy versus 5.9 Gy; p = 0.2) and retinas (8.7 Gy 
versus 8.6 Gy; p = 0.9) did not differ significantly between the 
types of plans.  
Conclusions: Using commercially available treatment planning 
software, dose painting for high-grade gliomas was planned with 
good BTV coverage and no significant change in the dose 
delivered to OARs. 
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Purpose: Evidence-based guidelines confirm a survival 
advantage of adjuvant radiotherapy (ART) for prostatectomy 
(RP) patients with high-risk pathologic features. Delayed referral 
for salvage radiotherapy is under evaluation as an alternative 
strategy, and current Ontario guidelines recommend radiation 
oncology (RO) referral of high-risk cases for discussion of options. 
We sought to evaluate factors associated with referral and use 
of ART after RP for patients with adverse pathology in a recently 
diagnosed cohort.  
Methods and Materials: This retrospective study used electronic 
treatment records linked to Ontario's population-based cancer 
registry and pathology records. Multivariable regression analysis 
was used to evaluate clinical and health systems factors 
associated with radiation oncology (RO) consultation and ART use 
within six months post-RP. 
Results: From January to November 2012, 2663 prostate cancer 
patients (mean age 61.3, s.d. 6.6 years) received RP in Ontario. 
Following RP, 1130 (42.3%) had at least one high-risk pathologic 
feature as a guideline indication for referral: extracapsular 
extension (ECE, 33.2%), seminal vesicle invasion (SVI, 10.1%), or 
positive margins (20.4%). Of these, 466 (41.2%) were seen by RO 
within six months of RP, of which 52.6% received ART. Of the 885 
patients with adverse pathologic risk factors who did not receive 
ART, 75.0% were never assessed by RO. Multivariate analysis 
confirmed that RO assessment within six months was more 
frequent amongst patients with adverse pathology, including 
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positive margins [OR 4.15(3.15-5.47); p < 0.0001], ECE [OR 
5.78(4.41-7.58); p < 0.0001], SVI [OR 4.10(2.88-5.85); p < 
0.0001], and Gleason score 8-10 [OR 2.90(1.97-4.26); p < 
0.0001]. Cancer centre was also predictive of referral rates 
(range 5.68% to 65.63% p < 0.0001). Patients seen by RO post-RP 
were almost twice as likely to have seen RO prior to RP [OR 
1.94(1.51-2.49); p < 0.0001]. Patient age, distance from an RT 
facility, neighbourhood income quintile, RP centre surgical 
volume, and affiliation of RP hospital with a cancer centre were 
not associated with the likelihood of RO consultation. On 
multivariate analysis of determinants of receiving ART, younger 
age [OR 1.029(1.004-1.054); p = 0.024] and adverse pathologic 
features, including positive margins [OR 4.34(3.09-6.11); p < 
0.0001], ECE [OR 8.13(5.26-12.50); p < 0.0001], SVI [OR 
3.33(2.32-4.81); p < 0.0001], and Gleason score 8-10 [OR 
2.53(1.68-3.82); p < 0.0001] remained strongly associated with 
the use of ART. The use of ART varied significantly across cancer 
centre regions (range 1.14% to 19.37% of all RP patients, p = 
0.0002). 
Conclusions: Over 40% of patients have high-risk features 
following RP and may benefit from ART, but many do not receive 
early RO referral. Cancer Centre is strongly predictive of both 
referral and ART use. An effort should be made to understand 
and reduce large inter-centre variations in access to RT post-RP 
for patients with high-risk prostate cancer. 
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Purpose: Choroidal metastases are an ominous sign of advanced 
systemic disease and a substantial source of morbidity causing 
visual impairment in many. External beam radiotherapy (RT) is 
an effective palliative treatment for choroidal metastases aimed 
at preserving vision and obtaining local tumour control. This 
study reports the outcomes of delivery of 20 Gy in 5 fractions in 
this palliative setting. 
Methods and Materials: This retrospective chart review included 
patients treated in the Ocular Oncology clinic at a large tertiary 
cancer centre who received RT (20 Gy in 5 fractions) for 
choroidal metastases between January 1999 and November 2012. 
Primary outcome measures were change in visual acuity and 
tumour response. Secondary outcomes included toxicities of RT 
(CTCAE version 4.0), tumour control, and overall survival (OS) 
from the date of choroidal metastases diagnosis. The following 
variables were evaluated using univariate and multivariable cox 
regression models for their association with OS: tumour 
histology, presence of symptoms, number of choroidal 
metastases, unilateral versus bilateral choroidal involvement, 
and interval between primary cancer diagnoses and choroidal 
metastases. 
Results: Fifty-five patients with 71 involved eyes were 
evaluated. Median follow up was 12 months (range 1-49). 
Decreased vision was the presenting symptom in 43 eyes (61%). 
Visual acuity improved from a median of 20/70 at baseline to 
20/40 at last follow up, and remained stable or improved in 56 
eyes (80%). Tumour shrinkage was observed in 64 eyes (91%) with 
complete response in 47 eyes (67%). Metastases progressed in 
four eyes (6%). Of the 39 patients presenting with unilateral 
choroidal disease (all were treated with a single lateral field, 
which resulted in 50-80% of the prescription dose to the 
contralateral choroid), only one developed contralateral 
choroidal metastases at 11 months after RT. Median survival 
after diagnosis of choroidal metastases was 13 months (95% CI: 
9-19) with Kaplan-Meier estimates of 50% (36-62), 23% (12-35), 
and 8% (3-18) at one, two, and three years, respectively. Acute 
toxicities were not experienced in 49 (89%) patients while five 
patients had transitory eye dryness (Grade 1) and one patient 
had episcleritis (Grade 1). Late toxicities included seven (10%) 
with optic neuropathy, four (6%) with cataracts, one (1%) with 
retinopathy, five (7%) with pigmentary maculopathy, and one 
(1%) with neovascular glaucoma. No variables were statistically 
significantly associated with OS. 
Conclusions: A short fractionation schedule of 20 Gy in 5 
fractions is a well-tolerated treatment that effectively preserves 
vision and gains local tumour control for many patients with 
choroidal metastases. This approach minimizes time spend in 
hospital for this palliative patient population and compares 
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Purpose: The Spinal Instability Neoplastic Score (SINS) was 
developed to identify patients requiring assessment by a spine 
surgeon. Patients are stratified into three groups: score 0-6 
(stable spine, no referral), 7-12 (potentially unstable, consider 
referral), and 13-18 (unstable, referral required). Purposes of 
study: (1) characterize the scores seen in a consecutive cohort 
of patients treated with spinal radiotherapy (RT) (2) assess 
referral patterns to spinal surgery (3) identify whether high SINS 
was prognostic of worse outcome following palliative RT. 
Methods and Materials: We retrospectively reviewed 
consecutive patients receiving palliative spine RT between 2012 
and 2013. The SINS was calculated based on CT simulation scan 
and clinical assessment. Charts were reviewed. Data analyzed 
using Kaplan-Meier and Cox models. A threshold of seven 
stratified patients into low- versus high-SINS groups. 
Results: One hundred and ninety-six patients were included. 
Patient demographics (median(range)): Age 66 (34-95), ECOG 2 
(0-4), Charlson Comorbidity Score 0 (0-4). Follow up was 6.1 (0.1-
42.3) months in all patients and 28.5 (0.2-42.3) months in living 
patients. By time of analysis, 83.7% had died.  
Median (range) SINS was 7 (1-18). SINS was 0-6, 7-12, and 13-18 
in 34%, 59% and 7% of patients. SINS indicated potentially or 
unstable spine in 84%, 63%, 53%, and 62% of breast, lung, 
prostate, and other cancer patients. Nineteen patients were 
referred to spine surgery (13 before and six after RT), with a 
surgery performed in zero of two patients with SINS 0-6, three of 
14 with SINS 7-12, and one of three with SINS 13-18. Stable spine 
on assessment, intact neurological status, and poor life 
expectancy were the most common reasons not to pursue surgery 
amongst surgically referred patients. SINS > 7, age, ECOG > 2, 
cancer type, solitary vertebral metastasis, control of primary, 
systemic therapy, and estimated prognosis were not predictive 
of surgery referral on univariate analysis. Outcomes 
(median(95%CI)) did not differ between low- versus high-SINS 
groups. Overall survival was 7.1 months (4.4-9.8, low) versus 6.4 
months (2.1-10.5, high), p = 0.262. Time to ECOG  ≥ 3 was 17.1 
months (5.2-28.9, low) versus 22.0 months (20.8-23.1, high), p = 
0.167. Freedom from subsequent intervention (RT or surgery) to 
the same vertebrae at one year was 81.7 +/- 5.5% (low) versus 
79.0% +/- 5.4% (high), p = 0.211. Ambulation at one year was 
84.2 +/- 4.7% (low) versus 90.2 +/- 4.0% (high), p = 0.085. 
Conclusions: Most patients with unstable or potentially unstable 
spines according to SINS were not referred to a spine surgeon. 
Higher SINS did not predict for worse survival, functional 
outcomes, or increased need for subsequent intervention. It is 
uncertain whether SINS would be predictive of outcomes in a 
cohort with better performance status. At the time of this study, 
many physicians were not using SINS to guide referral decisions. 
Whether and how SINS should be used to select patients for 
surgery requires further study. 
 
 
